Stock data
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of US$3.02B and net income of US$72.06M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$3.02B | US$1.11B | US$394.10M | US$72.06M | — |
| 2024 | US$2.79B | US$1.02B | US$249.33M | -US$116.89M | — |
| 2023 | US$2.39B | US$820.57M | US$204.37M | -US$83.99M | — |
| 2022 | US$2.21B | US$784.71M | -US$94.93M | -US$270.58M | — |
| 2021 | US$2.09B | US$768.97M | US$152.72M | US$13.16M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$796.20M | US$57.66M | — |
| 2026-03-31 | US$722.52M | US$62.26M | — |
| 2025-12-31 | US$814.32M | US$35.08M | — |
| 2025-09-30 | US$784.51M | US$2.37M | — |
| 2025-06-30 | US$724.51M | US$22.42M | — |
| 2025-03-31 | US$695.42M | US$12.20M | — |
| 2024-12-31 | US$730.52M | -US$31.08M | — |
| 2024-09-30 | US$702.47M | -US$0.16M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.